The role of levosimendan in acute heart failure complicating acute coronary syndrome: A review and expert consensus opinion

Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00669806%3A_____%2F16%3A10324636" target="_blank" >RIV/00669806:_____/16:10324636 - isvavai.cz</a>
Alternative codes found
RIV/00216208:11140/16:10324636
Result on the web
<a href="http://dx.doi.org/10.1016/j.ijcard.2016.05.009" target="_blank" >http://dx.doi.org/10.1016/j.ijcard.2016.05.009</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1016/j.ijcard.2016.05.009" target="_blank" >10.1016/j.ijcard.2016.05.009</a>

Result language
angličtina
Original language name
The role of levosimendan in acute heart failure complicating acute coronary syndrome: A review and expert consensus opinion
Original language description
On the basis of the existing literature and the clinical experience, the members of the panel agree that the inodilator levosimendan offers potential benefits in treatment of acute heart failure and/or cardiogenic shock complicating acute coronary syndrome due to a range of distinct effects including positive inotropy, restauration of ventriculo-arterial coupling, increases in tissueperfusion,and anti-stunning and anti-inflammatory effects. Levosimendan can be used alone or in combination with other agents, but it requires continuous monitoring due to the risk of hypotension. The panel agrees on the practical recommendations on indication, dosing, and monitoring.
Czech name
—
Czech description
—

Type
J<sub>x</sub> - Unclassified - Peer-reviewed scientific article (Jimp, Jsc and Jost)
CEP classification
FA - Cardiovascular diseases including cardio-surgery
OECD FORD branch
—

Project
—
Continuities
I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Publication year
2016
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Similar results(10)